29^th World Congress on Neurology and Therapeutics February 24-25, 2020 London, UK

Biography:

Abstract:

Biography:

Anna Jarrett is a doctoral prepared nurse practitioner certified by American Nurses’ Credentialing Center (ANCC).  She holds four nursing degrees, three national certifications, and has expertise in education, research, and practice. She is a master teacher, a seasoned researcher in the area of managing trauma outcomes, and she is a skilled advanced practice nurse in acute and primary care settings. Anna has practiced critical care and emergency nursing since 1978 in both small rural and larger metropolitan areas. She specializes in trauma intensive care, emergency, and disaster nursing. Anna maintains competency through practice, mentoring new faculty, and continued research efforts.

Abstract:

Biography:

Abstract:

Biography:

Nigora Kadyrkhodjayeva was born in Tashkent, Uzbekistan. She obtained her Bachelor's degree in Medicine from the Tashkent Medical Academy in 2006 and completed her residency of Neurology at Tashkent Institute of Postgraduate Medical Education in 2009. From 2006 till 2007 she was studying Psychiatry and Psychotherapeutics at the Tashkent Institute of Postgraduate Medical Education. Nigora has more than 10 years’ experience in Neurology. While studying her bachelor she volunteered in different cities of Uzbekistan within the program of USAID. She successfully cleared certification course of BLS & ACLS in 2018 and renewed in 2020. From September 2017, she is pursuing her PhD at the Tashkent Medical Academy. She has published several articles and abstracts in reputed journals.

Abstract:

Goal: The purpose of the study was to review the efficacy, safety and tolerability of botulinum toxin A (BTX-A) as a prophylactic treatment in adults with chronic daily headache (CDH). 

Material and methods: The study involved 100 patients with CDH comparing between two groups of patients. Group I, 54 patients (31 women and 23 men) treated by BTX-A, and group II, 46 patients (27 women and 21 men) treated with the classical method, with an average age of 35 ± 9 years. The patient’s condition in group I was evaluated on the third day, on the 7th day and on the 15th day after the BTX-A injection and assessed every 15 days for 3 months, in group II the patients were assessed every 15 days.

Results: After 3 months headache severity in group I: 2 (3,7%) patients had no changes, 7 (12,9%) patients with less than 50 percent reduction in pain, 23 (42,6%) reported 70 to 95 percent pain relief, and 22 (40,8%) had complete relief. Group II: 12 (26,1%) patients had no changes, 16 (34,8%) patients with less than 50 percent reduction in pain, 10 (21,7%) reported 70 to 95 percent pain relief, and 8 (17,4%) had complete relief. The mean change from baseline frequency of headaches ranged from 3 ± 1 headaches per 30‐day period in group I and 7±2 headaches in group II. The patients in group I used painkiller for an acute headache 4±1 day, compared to 10 ± 2 days for the group II per 30-day period.

Conclusion: In this study, BTX-A injections have been shown to be safe, well ‐tolerated, not any treatment-related serious adverse events reported. BTX-A injections recommended optimizing clinical outcomes for patients with CDH without using other prophylactic medications. Although, further observations are needed.

Biography:

Abstract:

Statement of the Problem: Approximately 70% of patients receiving oxaliplatin for colorectal cancer develop painful oxaliplatin- induced peripheral neuropathy (OIPN-P).  OIPN-P can persist up to 11 years after treatment is stopped, affecting quality of life, and contributing to falls, depression, and sleep loss. OIPN-P also necessitates decreased dosage during treatment, thereby decreasing treatment effectiveness and increasing mortality risk. The serotonin and norepinephrine reuptake inhibitor, duloxetine, is approved for treating OIPN-P, but is effective only in about 50% of patients. Recent work is suggestive that pretreating with tricyclic drugs can prevent onset of OIPN-P, but these drugs have serious side effects. We investigated whether pretreatment with duloxetine would prevent onset of OIPN-P in male and female rats in a model of oxaliplatin-induced hyperalgesia. Methodology: Rats were pretreated with duloxetine (15 mg; PO) for 7 days prior to and through oxaliplatin treatment, and for 20 days post oxaliplatin treatment. Rats were then tested for 6 days after all treatment stopped. The measure used was a 15 g von Frey filament applied to the left foot, which measures hyperalgesia, a sign of neuropathic pain. Findings: We found that rats pretreated with duloxetine presented with significantly less hyperalgesia through the testing period compared to control, and notably for the six days after all treatment stopped (p ≤ 0.003; p ≤ 0.13; males and females resp.). Conclusion and Significance: These pilot study findings are suggestive of the need for further study to determine whether pretreatment with duloxetine can prevent onset of OIPN-P.

Recent Publications:

1.Holden JE, Wagner, MA & Reeves, B. (2018). Anatomical Evidence for Lateral Hypothalamic Innervation of the Pontine A7 Catecholamine Cell Group in Rat. Neuroscience Letters. 668:80- 85.

2.Wagner MA, Jeong Y, Banerjee T, Yang J, & Holden JE (2016). Sex differences in hypothalamic-mediated tonic norepinephrine release for thermal hyperalgesia in rats. Neuroscience, 324:420-9.

3.Wardach J, Wagner M, Jeong Y, & Holden JE (2016). Lateral hypothalamic stimulation reduces thermal hyperalgesia through spinally descending orexin-A neurons in neuropathic pain. Western Journal of Nursing Research 38:292-307.

4.Holden JE, Wang E, Moes JR, Wagner M, Maduko A, & Jeong Y (2014). Differences in carbachol dose, pain condition and sex following lateral hypothalamic stimulation. Neuroscience, 270:226- 35.

5.Jeong Y, Moes JR, Wagner M & Holden JE (2012). The posterior hypothalamus exerts opposing effects on nociception via the A7 catecholamine cell group in rat. Neuroscience, 227:144-153.